Zhitong Finance App learned that on August 21, Hang Seng Index Company announced the results of a series of quarterly reviews of the Hang Seng Index up to June 30, 2026. Among them, Libang Pharmaceutical-B (09637) was included in the Hang Seng Composite Index. The index changes will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly.
Being included in the Hang Seng Composite Index this time means that Libang Pharmaceuticals is expected to become the Hong Kong Stock Exchange Standard at the same time. This is another important milestone since the company landed on the Hong Kong Stock Exchange on June 29, marking that its investment value and market position have been recognized by the Hong Kong Capital Market Authority Index System.
If successfully introduced, Rebang Pharmaceutical-B will enter the scope of southbound capital investment, and liquidity and valuation anchors are expected to improve at the same time. It is worth noting that the company will disclose its first interim results after listing on August 26, and the entry expectations and performance window are expected to double catalyze. With the gradient layout of “commercial product Meishinola base + multiple post-clinical innovative drug relays”, Libang Pharmaceutical is accelerating towards a leading platform in the field of innovative treatment of kidney disease.